Potential added value of an AI software with prediction of malignancy for the management of incidental lung nodules.
Artificial intelligence
Deep learning
Lung cancer
Lung nodule
Radiomics
Journal
Research in diagnostic and interventional imaging
ISSN: 2772-6525
Titre abrégé: Res Diagn Interv Imaging
Pays: France
ID NLM: 9918574385706676
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
04
08
2022
accepted:
09
08
2023
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
To determine the impact of an artificial intelligence software predicting malignancy in the management of incidentally discovered lung nodules. In this retrospective study, all lung nodules ≥ 6 mm and ≤ 30 mm incidentally discovered on emergency CT scans performed between June 1, 2017 and December 31, 2017 were assessed. Artificial intelligence software using deep learning algorithms was applied to determine their likelihood of malignancy: most likely benign (AI score < 50%), undetermined (AI score 50-75%) or probably malignant (AI score > 75%). Predictions were compared to two-year follow-up and Brock's model. Ninety incidental pulmonary nodules in 83 patients were retrospectively included. 36 nodules were benign, 13 were malignant and 41 remained indeterminate at 2 years follow-up.AI analysis was possible for 81/90 nodules. The 34 benign nodules had an AI score between 0.02% and 96.73% (mean = 48.05 ± 37.32), while the 11 malignant nodules had an AI score between 82.89% and 100% (mean = 93.9 ± 2.3). The diagnostic performance of the AI software for positive diagnosis of malignant nodules using a 75% malignancy threshold was: sensitivity = 100% [95% CI 72%-100%]; specificity = 55.8% [38-73]; PPV = 42.3% [23-63]; NPV = 100% [82-100]. With its apparent high NPV, the addition of an AI score to the initial CT could have avoided a guidelines-recommended follow-up in 50% of the benign pulmonary nodules (6/12 nodules). Artificial intelligence software using deep learning algorithms presents a strong NPV (100%, with a 95% CI 82-100), suggesting potential use for reducing the need for follow-up of nodules categorized as benign.
Identifiants
pubmed: 39076687
doi: 10.1016/j.redii.2023.100031
pii: S2772-6525(23)00010-8
pmc: PMC11265191
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100031Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.